Galectin Therapeutics GALT
NASDAQ GALT
$3.89 +0.13 (+3.46%)
As of: Oct 2, 2026 · 1:05 PM EDT

Galectin Therapeutics (GALT) Non Operating Interest Expenses (2018 - 2026)

Updated

Galectin Therapeutics' Non Operating Interest Expenses was $2 million in Q2 2026, up 9.7% from $1.83 million a year earlier and up 0.8% from the prior quarter.

Analysis

Galectin Therapeutics (GALT) Non Operating Interest Expenses (2018 - 2026) Analysis & Trends

On a trailing twelve-month basis, Galectin Therapeutics' Non Operating Interest Expenses was $7.75 million through Jun 30, 2026, up 14.2% year-over-year; for FY2025, it was $7.33 million, up 32.3% from FY2024.

  • Non Operating Interest Expenses has now increased for five consecutive years, with a five-year compound annual growth rate of 142.7% (FY2020 to FY2025).
  • In earlier years, Non Operating Interest Expenses was $5.54 million in FY2024 (+98.4%), $2.79 million in FY2023 (+170.3%), $1.03 million in FY2022 (+111.2%) and $489,000 in FY2021 (+462.1%).
  • The Q2 2026 figure marks the highest quarterly Non Operating Interest Expenses in data going back to Q1 2018.
  • Compared with a year earlier, Non Operating Interest Expenses has increased for 18 straight quarters, with growth averaging 43.8% over the last eight quarters.
  • Over the past five years, the year-over-year growth in Non Operating Interest Expenses ranged from 9.7% (Q2 2026) to 931.8% (Q1 2022).
  • Per Business Quant data, GALT's Non Operating Interest Expenses in the three quarters before Q2 2026 was $1.99 million (Q1 2026), $1.94 million (Q4 2025) and $1.82 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Galectin Therapeutics 257.29 Mn 257.29 Mn - 2.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.00 Mn
Mar 31, 2026 1.99 Mn
Dec 31, 2025 1.94 Mn
Sep 30, 2025 1.82 Mn
Jun 30, 2025 1.83 Mn
Mar 31, 2025 1.74 Mn
Dec 31, 2024 1.73 Mn
Sep 30, 2024 1.49 Mn
Jun 30, 2024 1.27 Mn
Mar 31, 2024 1.05 Mn
Dec 31, 2023 847,000.00
Sep 30, 2023 835,000.00
Jun 30, 2023 650,000.00
Mar 31, 2023 460,000.00
Dec 31, 2022 308,000.00
Sep 30, 2022 269,000.00
Jun 30, 2022 229,000.00
Mar 31, 2022 227,000.00
Dec 31, 2021 272,000.00
Sep 30, 2021 111,000.00
API Access

Galectin Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=GALT&period=max&api_key=YOUR_API_KEY